Gennova Biopharmaceuticals Ltd. has introduced a groundbreaking solution for paediatric cancer care with the launch of HAMSYL Junior, the first-of-its-kind 1500 IU paediatric pack size of pegaspargase. This development is set to revolutionize the treatment landscape for children battling Acute Lymphoblastic Leukaemia (ALL), a rare and challenging form of blood cancer.

The debut of HAMSYL Junior marks a significant milestone in addressing the unique needs of Indian paediatric patients. With its tailored 1500 IU vial pack size, HAMSYL Junior ensures precise dosing while minimizing wastage and the need for vial sharing, thereby offering a cost-effective solution for ALL management.

Gennova’s commitment to combating ALL dates back to 2014, with the introduction of HAMSYL®, a quality-assured pegaspargase available in a 3750 IU pack size. This pioneering product not only facilitated patient access but also reduced the cost of treatment, thereby transforming the landscape of ALL therapy in India. The safety and efficacy of HAMSYL® were further validated through real-world patient experiences, leading to its approval as a first-line therapy in 2019.

The development of HAMSYL Junior was spurred by insights from key opinion leaders in paediatric haematology, underscoring the need for a paediatric-specific pack size. Gennova’s swift response to this demand involved collaboration with regulatory authorities to modify the pack size, ensuring it aligns with the requirements of paediatric patients.

Dr. Sanjay Singh, CEO of Gennova Biopharma Limited, expressed pride in the launch of HAMSYL Junior, emphasizing its role in overcoming cost barriers and advancing ALL management in line with global standards. He reiterated Gennova’s commitment to democratizing healthcare and ensuring universal access to essential treatments.

HAMSYL Junior features a 1500 IU pack size with a 2.0 mL fill volume, maintaining the same API strength (750 IU/mL). This innovation represents a significant stride towards providing Indian paediatric patients with a tailored and accessible treatment option.

Gennova Biopharmaceuticals Ltd., headquartered in Pune, India, is dedicated to the research, development, and manufacturing of biotechnology-based products for human, veterinary, and agricultural use. As a subsidiary of Emcure Pharmaceuticals Ltd., Gennova remains at the forefront of advancing healthcare solutions to address unmet medical needs.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.